Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 27;7(5):97-100.
doi: 10.1002/cld.545. eCollection 2016 May.

Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma

Neehar D Parikh  1 , Amit G Singal  2   3
Affiliations
Review

Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma

Neehar D Parikh et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment‐responsive HCC: patient with complete response to therapy 3 months after TACE. Arrow denotes pretreatment tumor (left) and response to therapy with lack of arterial enhancement (right).
Figure 2
Figure 2
Treatment‐nonresponsive HCC: Patient with progressive disease over 6 months despite TACE. Arrow shows initial lesion pretreatment (left) and interval progression, with several new HCC nodules after treatment (right).
Figure 3
Figure 3
Forest plot of posttransplant HCC recurrence rates among patients who were downstaged to within Milan criteria.
See this image and copyright information in PMC

References

    1. Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, et al. Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 2015;61:1643‐1650. - PMC - PubMed
    1. Sotiropoulos GC, Molmenti EP, Losch C, Beckebaum S, Broelsch CE, Lang H. Meta‐analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007;12:527‐534. - PubMed
    1. Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014;60:1957‐1962. - PubMed
    1. Mehta N, Heimbach J, Harnois DM, Dodge JL, Burns JM, Lee D, et al., eds. Short Waiting Time Predicts Early Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Study Supporting the “Ablate and Wait” Principle. The Liver Meeting; 8 November 2014; Boston, MA.
    1. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19:1343‐1353. - PMC - PubMed